You are here

Adjuvant and Neoadjuvant Therapy

Adjuvant therapy with chemotherapy, irradiation, or a combination of these approaches has been used to enhance the potential benefit of surgery for patients with resectable stomach or GEJ cancer. Clinical trials have assessed therapy given prior to surgery (neoadjuvant), following surgery (adjuvant), or both before and after surgery (perioperative). The results of surgery alone for resectable gastric cancer have already been presented and justify the evaluation of both adjuvant irradiation and systemic chemotherapy with the intent of reducing local-regional and systemic risks of relapse and thereby improving survival.